Intelligence Feed event · Policy · 2026-10-21

    Ascentage Pharma wins China BTD for lisaftoclax combination therapy

    Question

    Ascentage Pharma wins China BTD for lisaftoclax combination therapy

    Direct answer

    Ascentage Pharma obtained Breakthrough Therapy Designation from the Chinese National Medical Products Administration for its investigational Bcl-2 inhibitor lisaftoclax in combination with BTK inhibitor acalabrutinib. The designation targets first-line treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma. Breakthrough status establishes access to expedited NMPA guidance and prioritized evaluation during registration filing. This milestone strengthens clinical validation for Ascentage's oncology portfolio as it advances toward potential domestic commercial authorization.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-21
    Published
    2026-10-21
    Revision
    1 · 2026-10-21

    Cite as: Market Ontology, “Ascentage Pharma wins China BTD for lisaftoclax combination therapy”, revision 1, evidence through 2026-10-21. https://marketontology.com/market-events/2026-10-21/ascentage-pharma-wins-china-btd-for-lisaftoclax-combination-therapy-32a99f

    POLICY
    Ascentage Pharma wins China BTD for lisaftoclax combination therapy
    Ascentage Pharma obtained Breakthrough Therapy Designation from the Chinese National Medical Products Administration for its investigational Bcl-2 inhibitor lisaftoclax in combination with BTK inhibitor acalabrutinib. The designation targets first-line treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma. Breakthrough status establishes access to expedited NMPA guidance and prioritized evaluation during registration filing. This milestone strengthens clinical validation for Ascentage's oncology portfolio as it advances toward potential domestic commercial authorization.
    AAPG
    Impact
    66
    YESTERDAY
    SIG
    88%
    AAPG
    Ascentage Pharma wins China BTD for lisaftoclax combination therapy
    Ascentage Pharma obtained Breakthrough Therapy Designation from the Chinese National Medical Products Administration for its investigational Bcl-2 inhibitor lisaftoclax in combination with BTK inhibitor acalabrutinib. The designation targets first-line treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma. Breakthrough status establishes access to expedited NMPA guidance and prioritized evaluation during registration filing. This milestone strengthens clinical validation for Ascentage's oncology portfolio as it advances toward potential domestic commercial authorization.
    → Accelerated regulatory review timelines shorten expected drug commercialization horizons, enhancing AAPG discounted pipeline cash flows.
    Impact
    Ascentage Pharma obtained Breakthrough Therapy Designation from the Chinese National Medical Products Administration for its investigational Bcl-2 inhibitor lisaftoclax in combination with BTK inhibitor acalabrutinib. The designation targets first-line treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma. Breakthrough status establishes access to expedited NMPA guidance and prioritized evaluation during registration filing. This milestone strengthens clinical validation for Ascentage's oncology portfolio as it advances toward potential domestic commercial authorization.
    Affected
    AAPG
    Transmission
    Accelerated regulatory review timelines shorten expected drug commercialization horizons, enhancing AAPG discounted pipeline cash flows.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    AAPGregulatory fast-tracking shortening time-to-market for lead oncology drug candidateUp1-4wAscentage Pharma announced lisaftoclax received Breakthrough Therapy Designation from China's NMPA for CLL/SLL.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month